Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung CancerMay 25, 2018
[OncoTargets and Therapy] Management of brain metastases in patients with EGFR-mutant NSCLC is controversial. In this study, researchers find combination and sequential treatment with EGFR-TKIs, chemotherapy, and radiotherapy is beneficial.
In this phase 2 study, researchers randomly assigned 79 patients with immunotherapy-naive melanoma with brain metastases to receive either nivolumab plus ipilimumab or nivolumab alone.
Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.
A retrospective analysis presented at 2017 SABCS reveals the factors that indicate a higher risk of developing brain metastases for women with HER2+ breast cancer.
Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months in the last decade.
Longer survival was achieved with stereotactic radiosurgery (SRS) alone than with whole-brain radiation therapy (WBRT) in patients with fewer than 4 brain metastases from NSCLC or breast cancer.
In patients previously treated with crizotinib for ALK-positive NSCLC and brain metastases, ceritinib treatment elicited clinically meaningful whole-body and intracranial responses with an acceptable tolerability profile.
For patients with non-small cell lung cancer who have EGFR mutations and brain metastases, progression-free survival was improved with afatinib compared to chemotherapy.
Radiosurgery and close monitoring is recommended to better preserve cognitive function in newly diagnosed brain metastases.
Data clearly demonstrated stereotactic radiosurgery (SRS) alone offered benefits for younger patients with limited metastases.
A blue-ribbon team of national experts stated that professional pessimism and out-of-date myths rather than current science may compromise the care of patients with brain cancer.
Imaging with a molecular imaging tracer can help distinguish radiation-induced lesions from new tumor growth in patients who have been treated with radiation for brain metastases, according to new research.
Researchers are suggesting that high-dose interleukin-2 (HD IL-2) therapy should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy, based on the encouraging results of a small retrospective review.
Intraventricular chemotherapy to the brain improved symptoms and survival in persons with leptomeningeal carcinomatosis following lung cancer.
Researchers have identified a novel signature of circulating tumor cells (CTCs) from breast cancer that metastasize to the brain.
Combining trastuzumab and lapatinib with an anti-VEGFR2 antibody dramatically improved survival in HER2 breast cancer with brain metastases.
A new study suggests radiotherapy may hold clinical promise for the control of local lymph node bed recurrence of malignant melanoma.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|